financetom
Business
financetom
/
Business
/
Finlay Minerals Announces $1 million Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Finlay Minerals Announces $1 million Non-Brokered Private Placement of Flow-Through Shares and Non-Flow-Through Units
May 26, 2025 1:53 PM

09:17 AM EDT, 05/26/2025 (MT Newswires) -- Finlay Minerals ( FYMNF ) on Monday said it plans to complete a non-brokered private placement for aggregate gross proceeds to the company of up to $1 million.

The offering will include the issuance of any combination of flow-through (FT) shares at a price of $0.11 each and non-flow-through (NFT) units at a price of $0.10 each. The private placement is subject to a minimum offering amount of $500,000, to be raised through any combination of FT shares and NFT units.

Each NFT unit will be made up of one non-flow-through common share of the company and one two-year non-flow-through common share purchase warrant to buy one NFT share at a price of $0.20 each.

The closing of the private placement is expected to occur on or about June 9, with the gross proceeds slated for exploration of the company's SAY, JJB and Silver Hope properties, and for general working capital purposes. The company added that it will use the gross proceeds from the issuance of FT shares to incur "Canadian exploration expenses" and qualify as "flow-through mining expenditures." The closing of the private placement is subject to certain closing conditions, including the approval of the TSXV.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Airbus keeps top spot with 766 jet deliveries in 2024
Airbus keeps top spot with 766 jet deliveries in 2024
Jan 9, 2025
PARIS, Jan 9 (Reuters) - Airbus delivered 766 airliners in 2024 and looked certain to maintain leadership of the jetmaking industry for a sixth year as arch-rival Boeing ( BA ) recovers cautiously from a prolonged internal crisis, company data showed on Thursday. The European planemaker fell fractionally short of a headline target of around 770 jets but was expected...
Diageo's Challenges Posed by GLP-1 Weight-Loss Drugs Cited by Fundsmith Manager for Selling Stake
Diageo's Challenges Posed by GLP-1 Weight-Loss Drugs Cited by Fundsmith Manager for Selling Stake
Jan 9, 2025
12:02 PM EST, 01/09/2025 (MT Newswires) -- Diageo ( DEO ) shares were on the chopping block for UK fund manager Terry Smith during 2024, with the veteran investor questioning whether the spirits and brewery company will be up to the potential challenge posed by GLP-1 weight-loss drugs on alcohol producers. In his annual message to Fundsmith clients, Smith this...
Factbox-Corporate America pledges donations for Trump's inauguration
Factbox-Corporate America pledges donations for Trump's inauguration
Jan 9, 2025
(Reuters) -Big companies from Wall Street to Silicon Valley are pledging donations to Donald Trump's inaugural fund before his Jan. 20 return to the White House, hoping to establish a positive rapport with his new administration. The companies include: ALPHABET Alphabet's Google has donated $1 million, a company spokesperson said. AMAZON.COM Amazon is donating $1 million. The company will broadcast...
Rigel Pharmaceuticals Says Potential Myelodysplastic Syndromes Therapy Gets FDA Orphan Drug Status
Rigel Pharmaceuticals Says Potential Myelodysplastic Syndromes Therapy Gets FDA Orphan Drug Status
Jan 9, 2025
12:07 PM EST, 01/09/2025 (MT Newswires) -- Rigel Pharmaceuticals ( RIGL ) said Thursday that the US Food and Drug Administration granted orphan drug designation to R289 for treatment of patients with myelodysplastic syndromes, or MDS. The company said it is conducting a phase 1b study to evaluate the investigational drug's safety, tolerability, pharmacokinetics and preliminary activity in MDS. FDA's...
Copyright 2023-2026 - www.financetom.com All Rights Reserved